Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Delaying Alzheimer’s is worth trillions

Executive Summary

New drugs to delay the onset of Alzheimer's disease by five years would have a social benefit to Americans of as much as $4 trillion over the next four decades, according to a study sponsored by Accelerate Cure and Treatments for Alzheimer's Disease. A drug delaying onset of disease by one year would produce a benefit worth $1.2 billion over the same period. These findings demonstrate the benefits to be gained by giving promising Alzheimer's treatments "the same priority review" accorded drugs for diseases such as cancer and HIV/AIDS, ACT-AD Chair Daniel Perry contends...
Advertisement

Related Content

Rethinking Alzheimer's: Mapping Out an Approval Process
Advertisement
UsernamePublicRestriction

Register

PS048375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel